Patients with myeloma are at risk for serious and life-threatening thromboembolic events because of their disease, individual risk factors, and antimyeloma or other medications. The International Myeloma Foundation's Nurse Leadership Board developed this consensus statement for assessment and prevention of thromboembolic events. Prophylactic measures are categorized as mechanical, regimen related, and antithrombotic drug, based on individual and myeloma-related risk factors. Aspirin is suggested for patients with no or one risk factor, low-molecular-weight heparin or full-dose warfarin for patients with two or more risk factors, and low-molecular-weight heparin or full-dose warfarin for all patients with therapy-related risks, including high-dose dexamethasone, doxorubicin, or multiagent chemotherapy.
T hromboembolic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE), are among the adverse events that can affect patients with multiple myeloma. Patients are at risk for the serious and potentially life-threatening events because of their disease, the presence of individual risk factors, and antimyeloma agents or other medications. Although use of the novel immunomodulatory drugs lenalidomide (Revlimid ® , Celgene Corporation) and thalidomide (Thalomid ® , Celgene Corporation) and the proteasome inhibitor bortezomib (Velcade ® , Millennium Pharmaceuticals, Inc.) have increased response rates and survival times for patients with multiple myeloma in recent years (Ghobrial et al., 2007; Manochakian, Miller, & Chanan-Khan, 2007; Rajkumar et al., 2005; Richardson & Anderson, 2006; Richardson, Hideshima, Mitsiades, & Anderson, 2007) , their use has been associated with an increased risk of thromboembolic events. The increase is related, in part, to administration of concomitant medications, including dexamethasone (Bennett et al., 2006; Celgene Corporation, 2007a , 2007b Durie et al., 2006; Palumbo et al., 2008; Rajkumar & Gertz, 2006; Zonder et al., 2006) . Thromboembolic events have been reported in patients receiving singleagent bortezomib, but at a much lower rate than that observed in patients with multiple myeloma treated with other agents, including lenalidomide or thalidomide (Celgene Corporation, 2007a , 2007b Harousseau et al., 2006; Lonial et al., 2007) . However, patients receiving bortezomib may be at risk for DVT and PE as a result of other risk factors, including some concomitant therapies.
The International Myeloma Foundation's Nurse Leadership Board, in recognition of the need for specific recommendations on managing key side effects of the novel antimyeloma agents, developed this consensus statement for the assessment and prevention of thromboembolic events, including DVT and PE, associated with novel therapies. The recommendations are designed to be used by healthcare providers in any type of medical institution (Bertolotti et al., 2007 (Bertolotti et al., , 2008 .
Issue Statement
Certain populations are at increased risk for thromboembolic events, including DVT and PE. Patients with cancer are among those with an increased risk for thromboembolic events (Heit et al., 2000 (Heit et al., , 2002 Otten et al., 2004; Prandoni, 2005; Van Gerpen & Mast, 2004) , and patients with multiple myeloma may incur an even higher incidence (Hussein, 2006; Palumbo et al., 2008) . Some combination treatments and concomitant therapies for multiple myeloma also may increase the incidence of thromboembolic events (Palumbo et al.) .
Disruption of the vascular endothelium by trauma, surgery, or disease can expose the subendothelium to clotting elements in the blood. In normal coagulation, platelet activation, granule secretion, and aggregation are followed by activation of the plasma coagulation cascade, ultimately leading to fibrin formation. Thrombosis can result from the unregulated activation of coagulation that occurs with continued endothelial damage, reduced blood flow in deep veins, and hypercoagulability. The resulting thrombus may obstruct blood vessels partially or completely or may dislodge from the site of formation to become an embolus (Handin, 2005; Story, 2006; Viale & Schwartz, 2004) .
Thromboembolic events can produce life-altering complications, affecting physiologic functions such as breathing, cognition, and overall function, and should be considered medical emergencies. Thromboembolic events can permanently affect the lives of patients and their families. Impairment resulting from thromboembolic events can interfere with therapy, treatment options, drug combinations, and patient adherence.
Patient and Caregiver Educational Recommendations
Patient education, focused nursing assessment, and proactive prophylaxis against thromboembolic events may increase positive patient outcomes. Nursing opportunities include identifying and recommending prophylaxis against thromboembolic events in conjunction with the healthcare team and implementing prophylaxis algorithms such as those included in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology™ for venous thromboembolic disease (NCCN, 2007) , the International Myeloma Working Group (IMWG) consensus statement recommendations (Palumbo et al., 2008) , this consensus statement, and other nursing practices that have been identified to reduce the risk of thromboembolic events.
Global Statement
Recommendations for prevention and prophylaxis of thromboembolic events in patients with multiple myeloma depend on institutional practices, drug therapies and combinations, and factors specific to individual patients (e.g., concomitant illnesses, medical history, cost of therapy, insurance, patient abilities, adherence, allergies and sensitivities).
Tool for Grading Thromboembolic Events
Healthcare professionals can quantify the severity of thromboembolic events with the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE). The NCI CTCAE are used for identifying treatment-related adverse events to facilitate the evaluation of new cancer therapies, treatment modalities, and supportive measures. For most adverse events, the NCI CTCAE defined grades 1 through 5 using unique clinical descriptions; each grade is assigned a severity: grade 1 is mild, grade 2 is moderate, grade 3 is severe, grade 4 is life threatening or disabling, and grade 5 is death related to the adverse event. grades 2 through 4 (NCI, 2006) . The events are included under the categories "thrombosis/embolism (vascular access related)" and "thrombosis/thrombus/embolism," and the catregory contains no grade 1 (mild) adverse event. The grades may be used for monitoring thromboembolic event toxicities and determining the need for intervention.
Assessment of Risk factors
Ongoing and focused nursing assessment, proactive prophylaxis, and prompt recognition and diagnostic workup of potential or actual thromboembolic events, particularly DVT and PE, can help patients with multiple myeloma achieve positive outcomes. Figure 1 lists general risk factors for thromboembolic events. Assessment tools to determine risk for venous thromboembolism and DVT are available for practitioners and patients (Caprini, 2006; Coalition to Prevent Deep-Vein Thrombosis, 2006) . The IMWG consensus statement for the prevention of thromboembolic events associated with thalidomide and lenalidomide in the treatment of patients with multiple myeloma relies on the number of individual and myeloma-related risk factors to determine specific recommendations (Palumbo et al., 2008) .
If a thromboembolic event is suspected, a complete history should be taken and a laboratory workup should be performed. Figure 2 lists the signs and symptoms of DVT and PE, which can be used for physical assessment. Table 2 summarizes the tests that are used to diagnose DVT and PE.
As mentioned, therapy with lenalidomide or thalidomide may increase the risk of thromboembolic events for patients with multiple myeloma, particularly in combination with other antimyeloma agents and concomitant medications. Table 3 lists therapy-related risk factors for thromboembolic events. Although the risk for thromboembolic events with lenalidomide or thalidomide administered as a single agent is low, both immunomodulatory drugs are indicated in combination with dexamethasone for the treatment of multiple myeloma. Low-dose dexamethasone should be distinguished from high-dose dexamethasone, which is defined as 480 mg or more per month; low-dose dexamethasone, defined as less than 480 mg per month, is not a risk factor for thromboembolic events (Palumbo et al., 2008) . In contrast, the proteasome inhibitor bortezomib is indicated for administration as a single agent; as such, it is not associated with an increased risk of thromboembolic events (Harousseau et al., 2006; Lonial et al., 2007; Millennium Pharmaceuticals, Inc., 2007) . However, some evidence suggests that the addition of bortezomib to regimens including lenalidomide and other combination therapies associated with thromboembolic events may decrease the incidence of such events (Barlogie et al., 2005; . Erythropoietin administered with lenalidomide or thalidomide is a risk factor for thromboembolic events, but administration of erythropoietin with bortezomib does not result in an increased risk of thromboembolic events (Harousseau et al.; Palumbo et al.) .
Recommendations for Prophylaxis
Clearly, recognizing factors that put patients at risk for thromboembolic events and instituting preventive measures are better than attempting to treat adverse events after they occur.
figure 1. General Risk factors for Thromboembolic Events
Note. Based on information from Austin et al., 2007; Bauer, 2001; Heit et al., 2000 Heit et al., , 2002 Joffe et al., 2004; Khorana et al., 2006; National Comprehensive Cancer Network, 2007; Palumbo et al., 2008; Prandoni, 2005; Prandoni et al., 2005; Spencer et al., 2007; Ven Gerpen & Mast, 2004 . Prophylactic measures against thromboembolic events may be categorized as mechanical, myeloma regimen related, and antithrombotic pharmaceutical (clot-preventing agent). Figure   3 describes recommendations for thromboembolic prophylaxis in each of the categories. Prophylaxis should take into account the patient's risk based on individual factors and the patient's antimyeloma and other therapeutic regimens. For example, measures to reduce the risk of thromboembolic events that are not related to myeloma or its therapy but are associated with individual patient factors (e.g., diet, exercise, lowering of cholesterol, weight reduction) may be recommended.
Some antithrombotic agents may be contraindicated in the presence of thrombocytopenia, renal impairment, or other comorbidities in patients with multiple myeloma because of their disease or antimyeloma therapy. For patients with a platelet count of 50 x 10 9 /L or less, aspirin and other anticoagulants generally should be held. Prophylaxis for thromboembolic events related to high-dose dexamethasone might consist of administration of low-molecular-weight heparin or heparin only on the days that dexamethasone is given. Less aggressive dosing schedules and lower doses of thalidomide and steroids alone or in combination may decrease incidence of thrombotic events; therefore, judicious dose reductions may increase quality of life and adherence to the therapeutic regimen.
The recommendations for prophylaxis presented in this article are made in consideration of the IMWG consensus statement (Palumbo et al., 2008) . The IMWG's recommendations for thrombotic prophylaxis that take into account individual or myeloma-related risk factors, such as those listed in Figure 1 and Table 3 , are as follows.
Aspirin for patients with zero or one individual or myeloma-• related risk factor Low-molecular-weight heparin or full-dose warfarin for pa-• tients with two or more individual or myeloma-related risk factors
Imaging examinations
Laboratory tests wheezing also may be present.
• Electrocardiogram right axis deviation or new right bundle branch block
Low-molecular-weight heparin or full-dose warfarin for all • patients with therapy-related risks, including high-dose dexamethasone, doxorubicin, or multiagent chemotherapy The labeling for thalidomide and lenalidomide recommends monitoring for signs and symptoms of thromboembolic events. According to the thalidomide label, preliminary data suggest that patients who are appropriate candidates may benefit from concurrent prophylaxis with aspirin or an anticoagulant (Celgene Corporation, 2007b) . The lenalidomide label states that the decision to use prophylaxis should be made after assessment of each patient's risk factors (Celgene Corporation, 2007a) .
Individual patient risk factors, the presence of multiple myeloma, and the use of antimyeloma therapies or other medications all contribute to the risk of serious and life-threatening thromboembolic events in patients with myeloma. Prophylactic measures based on individual and myeloma-related risk factors can reduce or eliminate the risk. 
Administration in combination with bortezomib or low-dose dexamethasone
Administration in combination with low-dose dexamethasone Administration in combination with erythropoietin with or without high-dose dexamethasone or with liposomal doxorubicin, in combination with lenalidomide, or in combination with VDT-PACE (bortezomib, dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, and etoposide)
Note. Based on information from Barlogie et al., 2005; Bennett et al., 2006 Bennett et al., , 2007 Celgene Corporation, 2007a , 2007b Harousseau et al., 2006; Hussein, 2006; Knight et al., 2006; Lonial et al., 2007; Manochakian et al., 2007; Millennium Pharmaceuticals, Inc., 2007; Offidani et al., 2005; Ortho Biotech Products, L.P., 2007; Palumbo et al., 2008; Zangari et al., 2002. Administration in combination with high-dose dexamethasone (defined as ≥ 480 mg per month), dexamethasone plus erythropoietin, erythropoietin, cyclophosphamide, or combinations containing doxorubicin (including liposomal doxorubicin) Administration in combination with high-dose dexamethasone, erythropoietin, melphalan, melphalan plus prednisone, or doxorubicin (including liposomal doxorubicin) with or without dexamethasone, or in combination with two or more chemotherapy agents with or without a corticosteroid Administration in combination with some multidrug therapies Note. Based on information from Barlogie et al., 2005; Bennett et al., 2006 Bennett et al., , 2007 Celgene Corporation, 2007b; Harousseau et al., 2006; Hussein, 2006; Knight et al., 2006; Lonial et al., 2007; Manochakian et al., 2007; Millennium Pharmaceuticals, Inc., 2007; Offidani et al., 2005; Ortho 
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Myeloma Regimen-Related Prophylaxis b
Reduce thalidomide from 100 mg PO to 50 mg PO daily, or reduce by 50 mg increments from current dosage. Administer dexamethasone 20-40 mg once weekly. Administer dexamethasone 20 mg days 1-4 only (monthly cycle) versus standard pulse (days 1-4, 9-12, and 17-20) . 
Antithrombotic Pharmaceutical Prophylaxis
key poinTs
Patients with cancer are at increased risk for developing blood clots (thromboembolic events). Patients with multiple myeloma may have an even higher risk of developing blood clots. Novel therapies used to treat myeloma include thalidomide and lenalidomide. These drugs, in combination with other medications, may increase the incidence of clots. Prevention of blood clots can reduce complications and contribute to successful treatment. Changes in your medication may be made by a healthcare provider based on your symptoms. Note. For more information, please contact the International Myeloma Foundation (1-800-452-CURE; www.myeloma.org). The foundation offers the Myeloma Manager TM Personal Care Assistant TM computer program to help patients and healthcare providers keep track of information and treatments. Visit http://manager.myeloma.org to download the free software. Note. Patient education sheets were developed in June 2008 based on the International Myeloma Foundation Nurse Leadership Board's consensus guidelines. They may be reproduced for noncommercial use.
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